mania
HONOLULU -- October 29, 2009 -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Defi
"By Jove, it's the reward circuitry!"
A dedicated member of the "to each his own taste" club, I'm all for freedom of speech. However, my website happens to discuss the highs and lows of sexual satiety in terms of the highs and lows of the typical addiction cycle. To my surprise (and theirs, I'm sure), men from all over the world showed up in my site's forum complaining of addiction to porn/masturbation.
PHILADEPHIA -- July 22, 2009 -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that a study published online in the peer-reviewed journal Child and Adolescent Psychiatry and Mental Health found once-daily Vyvanse® (lisdexamfetamine dimesylate) CII significantly reduced the symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in chi
Hollywood, FL -- July 1, 2009 -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced results from a Phase 3b study that found VYVANSE® (lisdexamfetamine dimesylate) CII demonstrated significant efficacy at 14 hours after administration during a simulated workplace environment study in adults with Attention Deficit Hyperactivity Disorder (ADHD).
EAST PROVIDENCE, RI -- A new study from Bradley Hospital and The Warren Alpert Medical School of Brown University, as well as two other institutions, adds to mounting evidence that clinicians consider irritability as a symptom when diagnosing pediatric bipolar disorder.
Titusville, NJ, May 27, 2009 ? A new instrument for improving patient understanding and acceptance of long-acting injectable antipsychotic therapy (LAT) has been published in the April edition of Psychiatry 2009.1 This novel, psychosocial approach encompasses Goal setting, Action planning, Initiating treatment, and Nurt
An errant enzyme linked to bipolar disorder, in the brain's prefrontal cortex, impairs cognition under stress, an animal study shows. The disturbed thinking, impaired judgment, impulsivity, and distractibility seen in mania, a destructive phase of bipolar disorder, may be traceable to overactivity of protein kinase C, suggests the study. It explains how even mild stress can worsen cognitive symptoms, as occurs in bipolar disoder, which affects two million Americans.
A study led by a UCLA Neuropsychiatric Institute researcher challenges standard treatment guidelines for bipolar depression that recommend discontinuing antidepressants within the first six months after symptoms ease. Study participants treated under the guidelines relapsed at nearly twice the rate of those who continued taking antidepressants in conjunction with their mood stabilizer medication during the first year after remission of acute bipolar depression. The researchers found no increased risk of manic relapse in those who continued the medication for one year.
Drug company AstraZeneca said it has submitted an application to the U.S. Food and Drug Administration for approval of quetiapine (Seroquel) as a treatment for acute mania associated with bipolar disorder, or manic-depressive illness. The application follows the completion of a clinical trial programme in bipolar disorder undertaken by the company which reportedly found quetiapine effective as a treatment of acute mania on two levels: as monotherapy (i.e to be prescribed on its own) and as adjunctive therapy with standard mood stabilising medication. These clinical trials have delivered strong and positive results in both the monotherapy and adjunctive therapy studies, which confirm quetiapine to be an ideal first line therapy for the treatment of acute mania associated with bipolar disorder, the company said.
